Salt Lake City, Utah – November 6, 2001 ARUP Laboratories,
Inc., a Utah-based clinical reference laboratory, and Scantibodies Clinical
Laboratory, Inc., a subsidiary of California-based Scantibodies Laboratory,
Inc., announced today that they will partner to offer improved parathyroid
disease testing to help doctors more accurately identify patients with
primary hyperparathyroid disease and monitor secondary hyperparathyroid
disease in dialysis patients. Over the last 25 years Scantibodies has
been an innovator in the development of parathyroid hormone (PTH) tests
that are used to detect and monitor parathyroid diseases. Their third-generation
PTH tests are available under the marks CAP™, CIP™ and CAP™/CIP™
Under this joint agreement, ARUP will be responsible for marketing and
servicing this new technology and will collect and report results on patient
samples from across the nation. Scantibodies will then perform a series
of third-generation parathyroid hormone assays on these patient samples.
“We are pleased to be taking this expansion step forward with our
improved PTH technology,” says Tom Cantor, president of Scantibodies.
“The collaboration with ARUP Laboratories allows physicians and
ultimately patients a broader access to the clinical benefits of this
improved diagnostic technology.”
In the United States, 50,000 people each year are diagnosed with primary
hyperparathyroid disease. Using the CAP assay, physicians may now detect
over 90 percent of patients with even mild forms of primary hyperparathyroidism.
Statistics available from studies show that the CAP assay has less overlap
between normal and mild hyperparathyroidism, resulting in an improved
detection rate of 96 percent, compared to the older second-generation
intact PTH assay of 72 percent.
Additionally, the over 300,000 patients receiving dialysis in the United
States each year require accurate assessment of bone turnover and parathyroid
function prior to treatment of secondary hyperparathyroidism. Scantibodies'
CAP/CIP ratio assay provides relative levels of authentic PTH and its
inhibitor. For a patient who is not yet receiving bone-affecting treatment,
a CAP/CIP ratio of less than one indicates that he or she has adynamic
low bone turnover disease, and consequently should not be placed on vitamin
D analog treatment. A ratio of one or greater indicates that the patient
has normal or high bone turnover and can be considered, if necessary,
for vitamin D analog treatments. Moreover, following treatment, physicians
may avoid oversuppression by monitoring the level of CIP. CIP and the
CAP/CIP ratio assays are significantly more accurate than the second-generation
intact PTH assay, and may help physicians better stratify treatment to
decrease conditions of soft tissue and vascular calcification, which are
leading causes of complications and death for dialysis patients.
“We are excited about this partnership,” remarks Ronald L.
Weiss, M.D., ARUP's senior vice president. “One of ARUP's
priorities is to offer the medical community access to innovative new
technologies that may improve the quality of patient care. Emerging third-generation
PTH assays are one such area that we continue to evaluate.”
ARUP Laboratories is a national full-service reference laboratory owned
by the Department of Pathology at the University of Utah Health Sciences
Center. ARUP is a worldwide leader in innovative laboratory research and
development, led by the efforts of the ARUP Institute for Clinical and
Experimental Pathology, LLC. With revenue of greater than $140 million
and more than 1,300 employees, ARUP offers over 2,000 tests and test combinations,
ranging from routine cytology screens to highly esoteric molecular and
genetic assays. ARUP's clients include university teaching hospitals,
multihospital groups, major commercial laboratories, group purchasing
organizations, military and government facilities, major clinics, and
major pharmaceutical firms.
Scantibodies Laboratory, Inc. (SLI), established in 1976, is a privately-owned
California corporation with 400 employees and a mission to improve patient
care through innovative immunoassays designed to more accurately diagnose
disease and monitor therapeutic effectiveness. Scantibodies Clinical Laboratory,
Inc. (SCL) is a wholly-owned subsidiary of SLI with the main focus of
providing third-generation PTH diagnostic services.
Scantibodies' Web site at www.scantibodies.com.